Abstract
AbstractBy utilizing Optum Life Sciences Claims Data, we constructed Real World Data (RWD) cohorts comprising over 3 million patients and simulated a clinical trial observational study design to evaluate over 200 FDA-approved drugs with COVID-19 repurposing potential, and identified a dozen candidates exhibiting significant reduction in the odds of severe COVID-19 outcomes such as death, intensive care unit (ICU) admission, hospitalization and pneumonia. Notably, certain drug combinations demonstrated effects comparable to those of COVID-19 vaccines. Furthermore, our study revealed a novel finding: a quantitative linear relationship between COVID-19 outcomes and overall patient health risks. This discovery enabled a more precise estimation of drug efficacy using the risk adjustment. The top performing drugs identified include emtricitabine, tenofovir, folic acid, progesterone, estradiol, epinephrine, disulfiram, nitazoxanide and some drug combinations including aspirin-celecoxib.
Publisher
Springer Science and Business Media LLC
Reference26 articles.
1. Wang, H. D. et al. Estimating excess mortality due to the COVID-19 pandemic: A systematic analysis of COVID-19-related mortality, 2020–21. Lancet 399, 1513–1536 (2022).
2. WHO. Coronavirus (COVID-19) Dashboard. https://covid19.who.int (2023).
3. Coronavirus (COVID-19) Vaccinations. Our World in Data. https://ourworldindata.org/covid-vaccinations (2023).
4. Clinical Studies for COVID-19. ClinicalTrials.gov, NIH U.S. National Library of Medicine. https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=&cntry=&state=&city=&dist= (2023).
5. Coronavirus (COVID-19) | Drugs. https://www.fda.gov/drugs/emergency-preparedness-drugs/coronavirus-covid-19-drugs (2023).
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献